| Literature DB >> 32752178 |
Wen-Ching Huang1, Chun-Hsu Pan2,3, Chen-Chan Wei4, Hui-Yu Huang5.
Abstract
A triathlon is an extremely high-intensity exercise and a challenge for physiological adaptation. A triathlete's microbiome might be modulated by diet, age, medical treatments, lifestyle, and exercise, thereby maintaining aerobiosis and optimum health and performance. Probiotics, prebiotics, and synbiotics have been reported to have health-promoting activities (e.g., immunoregulation and cancer prevention). However, few studies have addressed how probiotics affect the microbiota of athletes and how this translates into functional activities. In our previous study, we found that Lactobacillus plantarum PS128 could ameliorate inflammation and oxidative stress, with improved exercise performance. Thus, here we investigate how the microbiota of triathletes are altered by L. plantarum PS128 supplementation, not only for exercise performance but also for possible physiological adaptation. The triathletes were assigned to two groups: an L. plantarum 128 supplement group (LG, 3 × 1010 colony-forming units (CFU)/day) and a placebo group (PG). Both groups continued with their regular exercise training for the next 4 weeks. The endurance performance, body composition, biochemistries, blood cells, microbiota, and associated metabolites were further investigated. PS128 significantly increased the athletes' endurance, by about 130% as compared to the PG group, but there was no significant difference in maximal oxygen consumption (VO2max) and composition between groups. The PS128 supplementation (LG) modulated the athlete's microbiota with both significant decreases (Anaerotruncus, Caproiciproducens, Coprobacillus, Desulfovibrio, Dielma, Family_XIII, Holdemania, and Oxalobacter) and increases (Akkermansia, Bifidobacterium, Butyricimonas, and Lactobacillus), and the LG showed lower diversity when compared to the PG. Also, the short-chain fatty acids (SCFAs; acetate, propionate, and butyrate) of the LG were significantly higher than the PG, which might be a result of a modulation of the associated microbiota. In conclusion, PS128 supplementation was associated with an improvement on endurance running performance through microbiota modulation and related metabolites, but not in maximal oxygen uptake.Entities:
Keywords: L. plantarum PS128; SCFAs; exercise; gut microbiota; triathlete
Mesh:
Substances:
Year: 2020 PMID: 32752178 PMCID: PMC7468698 DOI: 10.3390/nu12082315
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1The effects of L. plantarum PS128 on exercise performance and body composition. The data are represented as mean ± SD. The endurance was record as exhaustive time with treadmill exercise, and maximal oxygen utilization (VO2max) was collected with gas exchange. PG and LG refer to the placebo and L. plantarum treatment groups, respectively. *: the significant difference between groups (p < 0.05).
Blood biochemistry analysis.
| Parameters | PG | LG | |
|---|---|---|---|
| Albumin (g/dL) | 4.7 ± 0.2 | 4.8 ± 0.2 | 0.691 |
| Alk-P (U/L) | 70.6 ± 21.3 | 76.7 ± 18.7 | 0.505 |
| BUN (mg/dL) | 16.5 ± 3.2 | 14.8 ± 2.7 | 0.072 |
| Creatinine (mg/dL) | 1.1 ± 0.1 | 1.01 ± 0.1 | 0.109 |
| Free Fatty acid (ng/mL) | 11.0 ± 2.8 | 11.7 ± 2.3 | 0.561 |
| AST (U/L) | 25.7 ± 14.5 | 21.8 ± 4.3 | 0.970 |
| ALT (U/L) | 13.9 ± 6.2 | 12.5 ± 2.8 | 0.970 |
| HDL Cholesterol (mg/dL) | 50.6 ± 4.7 | 50.7 ± 5.1 | 0.964 |
| LDH (U/L) | 268.8 ± 64.9 | 270.6 ± 50.5 | 0.946 |
| LDL Cholesterol (mg/dL) | 101.9 ± 17.8 | 107.5 ± 28.0 | 0.600 |
| Serum AC Sugar (mg/dL) | 82.1 ± 14.6 | 76.3 ± 20.2 | 0.471 |
| T-Cho/HDL-Cho | 3.3 ± 0.5 | 3.4 ± 0.6 | 0.744 |
| Total Cholesterol (mg/dL) | 166.9 ± 18.0 | 173.0 ± 34.8 | 0.629 |
| Total Protein (g/dL) | 7.2 ± 0.4 | 7.3 ± 0.5 | 0.582 |
| Triglyceride (mg/dL) | 111.9 ± 46.1 | 107.5 ± 50.1 | 0.840 |
| Uric Acid (mg/dL) | 5.8 ± 1.1 | 5.9 ± 1.0 | 0.833 |
LG and PG represent the L. plantarum PS128 and placebo treatment groups, respectively. LDH: lactate dehydrogenase, Alk-P: alkaline phosphatase, BUN: blood urea nitrogen, AST: aspartate aminotransferase, ALT: alanine aminotransferase.
Complete Blood cell analysis.
| Parameters | PG | LG | |
|---|---|---|---|
| Hb (g/dL) | 15.1 ± 1.6 | 14.8 ± 1.3 | 0.595 |
| Hct (%) | 15.0 ± 4.5 | 44.3 ± 3.9 | 0.571 |
| MCH (pg) | 30.4 ± 1.7 | 30.5 ± 1.2 | 0.988 |
| MCHC (g/dL) | 33.4 ± 0.4 | 33.4 ± 0.2 | 1.000 |
| MCV (fL) | 90.9 ± 4.4 | 92.1 ± 4.0 | 0.632 |
| WBCs (103/μL) | 8.5 ± 2.0 | 8.5 ± 2.2 | 0.731 |
| Basophil (%) | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.349 |
| Eosinophil (%) | 4.4 ± 2.7 | 3.4 ± 2.6 | 0.571 |
| Lymphocyte (%) | 21.0 ± 5.4 | 21.2 ± 4.8 | 0.982 |
| Monocyte (%) | 8.3 ± 2.1 | 8.9 ± 3.4 | 0.674 |
| Neutrophil (%) | 65.5 ± 7.9 | 65.6 ± 7.0 | 0.985 |
| Platelet (103/μL) | 247.2 ± 32.7 | 289.6 ± 50.4 | 0.049 |
| RBCs (106/μL) | 5.0 ± 0.5 | 4.9 ± 0.5 | 0.649 |
| NLR | 3.4 ± 1.4 | 3.3 ± 1.2 | 0.940 |
LG and PG represent the L. plantarum PS128 and placebo treatment groups, respectively. Hb: hemoglobin; Hct: hematocrit; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean cell volume; WBCs: white blood cells; RBCs: red blood cells; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-neutrophil ratio.
Figure 2Changes of the relative abundance at the phylum and genus levels. Top 10 abundance at the phylum (A) and genus (B) level.
Figure 3Firmicutes/Bacteroidetes ratio between groups.
Figure 4Relative abundance of predominant taxa at the genus level. Each value is presented as the mean ± SD, and the significance tests were conducted in each treatment population at the genus level. *: p < 0.05; **: p < 0.01.
Figure 5Changes of fecal microbial diversity: (A) Alpha diversity and (B) β diversity of athlete with L. plantarum PS128 (LG) and placebo (PG) treatment. *: the significant difference between groups; p < 0.05.
Figure 6Short-chain fatty acid (SCFA) analysis in the feces of the triathletes. The LG and PG represented the triathletes receiving L. plantarum PS128 and placebo treatment groups, respectively, and p-values < 0.05 were considered significant (*) in each treatment population.